JBHI
J-BHI publishes original papers describing recent advances in the field of biomedical and health informatics where information and communication technologies intersect with health, healthcare, life sciences and biomedicine.
Subscribe
for Updates

Pau Herrero
PauHerrero received the M.Eng. degree in industrial engineering from the University of Girona, Girona, Spain, in 2001, and the Ph.D. degree in control engineering from University of Angers, Angers, France, and University of Girona, Girona, Spain, in 2006.
After completing his Ph.D., he spent one year as a Postdoctoral Research Fellow at Doyle’s group, University of California Santa Barbara, CA, USA, working on an artificial pancreas project. After his stay in California, he spent two years at Sant Pau Hospital, Barcelona, Spain, working as a Research Fellow within CIBER-BBN research network leading different eHealth projects for the prevention and management of diabetes. He is currently a Research Fellow within the Centre for Bio-inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London, U.K. His main research interests include diabetes technology and intelligent antibiotic prescribing.
Associated articles
JBHI, Featured Articles
Advanced Insulin Bolus Advisor based on Run-To-Run Control and Case- Based Reasoning
Herrero, P. Pesl, M. Reddy, N. Oliver, P. Georgiou, and C. Toumazou
Insulin bolus calculators are simple decision support software tools incorporated in most commercially available insulin pumps to help people with Type 1 diabetes mellitus (T1DM) calculate the insulin doses...
Read more
Posted on 4 MAY 2015
JBHI, Featured Articles
Predicting Quality of Overnight Glycaemic Control in Type 1 Diabetes using Binary Classifiers
Amparo Guemes, Giacomo Cappon, Bernard Hernandez, Monika Reddy, Nick Oliver, Pantelis Georgiou, Pau Herrero
ype 1 diabetes management, maintaining nocturnal blood glucose within target range can be challenging. Although semi-automatic systems to modulate insulin pump delivery, such as low-glucose insulin suspension and the artificial pancreas, are starting to become a reality, their elevated cost and performance below user expectations is hindering their adoption...
Read more
Posted on 30 APR 2020